-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec content team editor A few days ago, Xencor announced that Zenas BioPharma has obtained the global development, production and commercialization rights of the research antibody obexelimab from Xencor
.
Obexelimab is a new type of bifunctional antibody that simultaneously targets FcγRIIb that inhibits B cell activity and CD19 antigen expressed by B cells for the treatment of autoimmune diseases
.
In autoimmune diseases, activated B cells are one of the main factors that attack one's own cells and tissues
.
Obexelimab is a potential "first-in-class" bifunctional antibody
.
Xencor modified the Fc end of a monoclonal antibody that binds to the CD19 antigen, increasing its affinity with FcγRIIb by 400 times
.
FcγRIIb is a receptor that inhibits the function of B cells.
After obexelimab binds to the CD19 antigen on the surface of B cells, its Fc terminal will automatically interact with FcγRIIb on the same cell, thereby inhibiting B cell receptor-mediated B cell activation and proliferation
.
Early clinical studies have shown that obexelimab can effectively inhibit B cell function without depleting cells, and has produced encouraging therapeutic effects in patients with a variety of autoimmune diseases
.
▲The mechanism of action of Obexelimab (picture source: Reference [2]) Dr.
Mu Hua, President and CEO of Zenas, said: “We are very happy to add obexelimab to the product pipeline.
Based on the research data obtained so far, we believe it is a treatment Potential'first-in-class' drug candidates for many autoimmune diseases
.
" Xencor President and CEO Dr.
Bassil Dahiyat said: "obexelimab can effectively and extensively block B cell activity without depleting B cells.
This is completely different from other B-cell targeted therapies
.
We and Zenas BioPharma are also committed to extensively and actively developing new therapies like obexelimab for patients with autoimmune diseases
.
"Reference: [1] Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor.
Retrieved November 24, 2021, from https:// 2] Interim Results of a Phase 2 Study of XmAb®5871, a Reversible B Cell Inhibitor, in IgG4-Related Disease.
From https://investors.
xencor.
com/static-files/e704e415-b58a-430a-bfdb-8a04795178e9 Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
.
Obexelimab is a new type of bifunctional antibody that simultaneously targets FcγRIIb that inhibits B cell activity and CD19 antigen expressed by B cells for the treatment of autoimmune diseases
.
In autoimmune diseases, activated B cells are one of the main factors that attack one's own cells and tissues
.
Obexelimab is a potential "first-in-class" bifunctional antibody
.
Xencor modified the Fc end of a monoclonal antibody that binds to the CD19 antigen, increasing its affinity with FcγRIIb by 400 times
.
FcγRIIb is a receptor that inhibits the function of B cells.
After obexelimab binds to the CD19 antigen on the surface of B cells, its Fc terminal will automatically interact with FcγRIIb on the same cell, thereby inhibiting B cell receptor-mediated B cell activation and proliferation
.
Early clinical studies have shown that obexelimab can effectively inhibit B cell function without depleting cells, and has produced encouraging therapeutic effects in patients with a variety of autoimmune diseases
.
▲The mechanism of action of Obexelimab (picture source: Reference [2]) Dr.
Mu Hua, President and CEO of Zenas, said: “We are very happy to add obexelimab to the product pipeline.
Based on the research data obtained so far, we believe it is a treatment Potential'first-in-class' drug candidates for many autoimmune diseases
.
" Xencor President and CEO Dr.
Bassil Dahiyat said: "obexelimab can effectively and extensively block B cell activity without depleting B cells.
This is completely different from other B-cell targeted therapies
.
We and Zenas BioPharma are also committed to extensively and actively developing new therapies like obexelimab for patients with autoimmune diseases
.
"Reference: [1] Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor.
Retrieved November 24, 2021, from https:// 2] Interim Results of a Phase 2 Study of XmAb®5871, a Reversible B Cell Inhibitor, in IgG4-Related Disease.
From https://investors.
xencor.
com/static-files/e704e415-b58a-430a-bfdb-8a04795178e9 Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
